Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Drug: Placebo to match SIM
Biological: Simtuzumab
Drug: Leucovorin
Drug: Irinotecan
Drug: Fluorouracil

First Posted Date: 2011-11-24

Last Posted Date: 2019-04-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 266

Registration Number: NCT01479465

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
Providence Saint Joseph Medical Center-Disney Family Cancer Center, Burbank, California, United States

and more 100 locations

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Biological: ganitumab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Other: placebo
Other: questionnaire administration

First Posted Date: 2011-11-17

Last Posted Date: 2016-06-28

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT01473303

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Radiation: Radiotherapy
Drug: Leucovorin
Biological: Cetuximab
Drug: Filgrastim
Drug: Erythropoetin
Drug: Cisplatin
Drug: Fluorouracil
Drug: Docetaxel

First Posted Date: 2011-11-08

Last Posted Date: 2017-05-09

Lead Sponsor: Drexel University College of Medicine

Target Recruit Count: 1

Registration Number: NCT01467115

Locations: 🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Folinic Acid
Drug: Oxaliplatin
Drug: 5-FU
Drug: Irinotecan
Drug: Bevacizumab
Drug: Cetuximab

First Posted Date: 2011-09-29

Last Posted Date: 2021-06-18

Lead Sponsor: UNICANCER

Target Recruit Count: 256

Registration Number: NCT01442935

Locations: 🇫🇷
Centre Val d'Aurelle, Montpellier, France

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-FU
Drug: FOLFOX regimen
Drug: bevacizumab [Avastin]
Drug: Placebo
Drug: leucovorin
Drug: onartuzumab [MetMAb]

First Posted Date: 2011-08-17

Last Posted Date: 2017-05-30

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 194

Registration Number: NCT01418222

Locations: 🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇺🇸
Toledo Comm. Onc. Program, Toledo, Ohio, United States
🇺🇸
Virginia Cancer Institute, Richmond, Virginia, United States

and more 20 locations

FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: Leucovorin
Drug: Fluorouracil
Other: laboratory biomarker analysis
Other: flow cytometry
Other: immunohistochemistry staining method
Other: pharmacological study
Drug: PF-04136309